

Sandostatin[®] LAR Depot (octreotide) – First-time generic

- On October 1, 2024, [Teva launched](#) an [AB-rated](#) generic version of Novartis' [Sandostatin LAR Depot \(octreotide\)](#) intramuscular injection.
- Sandostatin LAR Depot is approved for the following indications:
 - Long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy, is not an option
 - Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
 - Long-term treatment of the profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP)-secreting tumors.
- Octreotide is also available as brand delayed-release capsules ([Mycapssa[®]](#)) and generic subcutaneous or intravenous [injection](#).
 - Mycapssa is approved for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
 - Octreotide acetate injection is indicated to reduce blood levels of growth hormone and insulin growth factor-1 in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses; symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease; and treatment of the profuse watery diarrhea associated with VIP-secreting tumors.
- According to IQVIA[™], Sandostatin LAR Depot had annual sales of \$826 million as of July 2024.